<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><description>世事洞明皆学问，人情练达即文章</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 17 Apr 2021 10:08:46 +0800</pubDate><image><url>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</url><title>医药魔方 | wechat-feeds</title><link>http://MzA4MDA4MTIzMg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>一文详解｜2021年CSCO乳腺癌指南更新要点（上）</title><link>https://mp.weixin.qq.com/s/nY0jhTPcmyPIGd4kwdQqZg</link><description></description><content:encoded><![CDATA[一文详解｜2021年CSCO乳腺癌指南更新要点（上）]]></content:encoded><pubDate>Sat, 17 Apr 2021 08:59:14 +0800</pubDate></item><item><title>6月课程 | 创新药药学研究关键技术要求</title><link>https://mp.weixin.qq.com/s/0YHCSGJ5SN41KGJuDSTC1w</link><description></description><content:encoded><![CDATA[6月课程 | 创新药药学研究关键技术要求]]></content:encoded><pubDate>Sat, 17 Apr 2021 08:59:14 +0800</pubDate></item><item><title>益方生物提交科创板IPO申请：员工70名，Pre-IPO估值50亿；三代EGFR抑制剂已申报上市</title><link>https://mp.weixin.qq.com/s/N0K_6sA1ZgtW07IGymwG6g</link><description></description><content:encoded><![CDATA[益方生物提交科创板IPO申请：员工70名，Pre-IPO估值50亿；三代EGFR抑制剂已申报上市]]></content:encoded><pubDate>Fri, 16 Apr 2021 07:45:43 +0800</pubDate></item><item><title>默沙东终止4.25亿美元收购的新冠项目，全力聚焦“下一个希望”</title><link>https://mp.weixin.qq.com/s/AQqHazcGiRXhf4MruwYHAg</link><description></description><content:encoded><![CDATA[默沙东终止4.25亿美元收购的新冠项目，全力聚焦“下一个希望”]]></content:encoded><pubDate>Fri, 16 Apr 2021 07:45:43 +0800</pubDate></item><item><title>新型口服疗法获FDA突破性疗法认定，治疗1型糖尿病</title><link>https://mp.weixin.qq.com/s/RlPn-vGQJu7ZQCTqNa4HDw</link><description></description><content:encoded><![CDATA[新型口服疗法获FDA突破性疗法认定，治疗1型糖尿病]]></content:encoded><pubDate>Fri, 16 Apr 2021 07:45:43 +0800</pubDate></item><item><title>瑞德西韦后，下一个希望在何方？</title><link>https://mp.weixin.qq.com/s/7b3Nxiv_J7vJCcYxUiFMGw</link><description></description><content:encoded><![CDATA[瑞德西韦后，下一个希望在何方？]]></content:encoded><pubDate>Thu, 15 Apr 2021 07:37:10 +0800</pubDate></item><item><title>阿诺医药宣布Buparlisib（AN2025）治疗复发性或转移性头颈癌的全球III期临床完成首例患者给药</title><link>https://mp.weixin.qq.com/s/KxVaxXfZkYQKu4bXbjxC2w</link><description></description><content:encoded><![CDATA[阿诺医药宣布Buparlisib（AN2025）治疗复发性或转移性头颈癌的全球III期临床完成首例患者给药]]></content:encoded><pubDate>Thu, 15 Apr 2021 07:37:10 +0800</pubDate></item><item><title>3月肺癌月报 | 振奋！国产三代EGFR-TKI登顶柳叶刀子刊；百济PD-1亮相JAMA Oncol，晚期NSCLC一线战鼓不休</title><link>https://mp.weixin.qq.com/s/WufvaI6hnwbnuTj3TVBVlw</link><description></description><content:encoded><![CDATA[3月肺癌月报 | 振奋！国产三代EGFR-TKI登顶柳叶刀子刊；百济PD-1亮相JAMA Oncol，晚期NSCLC一线战鼓不休]]></content:encoded><pubDate>Thu, 15 Apr 2021 07:37:10 +0800</pubDate></item><item><title>医药魔方Med招聘：医学编辑、医学经理、医学数据经理</title><link>https://mp.weixin.qq.com/s/xoPLHiT3IZkl2B1qaLh-jg</link><description></description><content:encoded><![CDATA[医药魔方Med招聘：医学编辑、医学经理、医学数据经理]]></content:encoded><pubDate>Thu, 15 Apr 2021 07:37:10 +0800</pubDate></item><item><title>PPT+视频回放 | 2021AACR新机会分析</title><link>https://mp.weixin.qq.com/s/2wgYQwOFuDE0cM-aWfDbZQ</link><description></description><content:encoded><![CDATA[PPT+视频回放 | 2021AACR新机会分析]]></content:encoded><pubDate>Thu, 15 Apr 2021 07:37:10 +0800</pubDate></item><item><title>核素偶联药物（RDC）：黑色大幕，悄然开启</title><link>https://mp.weixin.qq.com/s/OVBNAGuNBCGK-QQzniCsow</link><description></description><content:encoded><![CDATA[核素偶联药物（RDC）：黑色大幕，悄然开启]]></content:encoded><pubDate>Wed, 14 Apr 2021 08:04:49 +0800</pubDate></item><item><title>先声药业在2021AACR年会上公布创新药重要布局--TNFR2</title><link>https://mp.weixin.qq.com/s/fkXiVMQCbFAJZd9zU8HURQ</link><description></description><content:encoded><![CDATA[先声药业在2021AACR年会上公布创新药重要布局--TNFR2]]></content:encoded><pubDate>Wed, 14 Apr 2021 08:04:49 +0800</pubDate></item><item><title>礼来新一代KRAS G12C抑制亮眼：临床前活性较AMG 510提高10倍</title><link>https://mp.weixin.qq.com/s/cBDM9_SUn95EsejFmF3aZw</link><description></description><content:encoded><![CDATA[礼来新一代KRAS G12C抑制亮眼：临床前活性较AMG 510提高10倍]]></content:encoded><pubDate>Wed, 14 Apr 2021 08:04:49 +0800</pubDate></item><item><title>德琪医药ATG-010(Selinexor)联合ATG-008 (Onatasertib)治疗三重打击DLBCL的协同效果显著</title><link>https://mp.weixin.qq.com/s/tpgF5tRp2-lvaanLGOGXBw</link><description></description><content:encoded><![CDATA[德琪医药ATG-010(Selinexor)联合ATG-008 (Onatasertib)治疗三重打击DLBCL的协同效果显著]]></content:encoded><pubDate>Wed, 14 Apr 2021 08:04:49 +0800</pubDate></item><item><title>肿瘤电场疗法晚期肺癌III期研究有望提前成功，Novocure/再鼎股价大涨</title><link>https://mp.weixin.qq.com/s/43NeaVGb8y9Lsaq7G27Qaw</link><description></description><content:encoded><![CDATA[肿瘤电场疗法晚期肺癌III期研究有望提前成功，Novocure/再鼎股价大涨]]></content:encoded><pubDate>Wed, 14 Apr 2021 08:04:49 +0800</pubDate></item><item><title>凌腾医药宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验</title><link>https://mp.weixin.qq.com/s/-vg2Ac7T-9FPspPisFMW9w</link><description></description><content:encoded><![CDATA[凌腾医药宣布开展卡妥索双抗治疗非肌层浸润性膀胱癌临床I/II期试验]]></content:encoded><pubDate>Tue, 13 Apr 2021 07:39:23 +0800</pubDate></item><item><title>康宁杰瑞在AACR 2021年会上公布KN046联合白蛋白紫杉醇治疗三阴乳腺癌的临床研究数据</title><link>https://mp.weixin.qq.com/s/FCaEmZ27m3Pd7Fm87tFfaw</link><description></description><content:encoded><![CDATA[康宁杰瑞在AACR 2021年会上公布KN046联合白蛋白紫杉醇治疗三阴乳腺癌的临床研究数据]]></content:encoded><pubDate>Tue, 13 Apr 2021 07:39:23 +0800</pubDate></item><item><title>不完美的治愈之光？奥希替尼辅助治疗适应症获批的几点思考</title><link>https://mp.weixin.qq.com/s/pP2W5xTahFDLa7a0jm-UBg</link><description></description><content:encoded><![CDATA[不完美的治愈之光？奥希替尼辅助治疗适应症获批的几点思考]]></content:encoded><pubDate>Tue, 13 Apr 2021 07:39:23 +0800</pubDate></item><item><title>直播预告 | 2021 AACR研发投资新机会</title><link>https://mp.weixin.qq.com/s/vKlZ6NE6fabs6YECR_63Vg</link><description></description><content:encoded><![CDATA[直播预告 | 2021 AACR研发投资新机会]]></content:encoded><pubDate>Tue, 13 Apr 2021 07:39:23 +0800</pubDate></item><item><title>2021 AACR的fast follow机会</title><link>https://mp.weixin.qq.com/s/f8AqI_gXI-j1VqvVnKgGpQ</link><description></description><content:encoded><![CDATA[2021 AACR的fast follow机会]]></content:encoded><pubDate>Mon, 12 Apr 2021 07:40:45 +0800</pubDate></item></channel></rss>